HLNE Stock Analysis: Hamilton Lane | NASDAQ
Asset Management | NASDAQ, USA | Market Cap: 6.366m USD | 12M Return: -25.6% | US4074971064 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 51.5M
EPS Trend: 95.9%
Qual. Beats: 2
Rev. Trend: 92.7%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 9.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Hamilton Lane Incorporated (NASDAQ: HLNE) is a Philadelphia-based private markets investment firm founded in 1991 that provides clients with access to private equity, venture capital, credit, and real assets through a range of structures, including direct investments, primary and secondary fund of funds, evergreen vehicles, and customized solutions. The firm invests across the full private equity life cycle, from early venture and growth equity to buyouts, distressed, and mezzanine financings, generally committing between $0.25 million and $100 million per transaction and typically taking majority stakes in small- to mid-sized companies.
Its geographic and sector reach is broad, spanning North America, Europe, Asia/Pacific, the Middle East, Africa, and Latin America, with portfolio exposure concentrated in technology, healthcare, financials, consumer, industrials, energy, and tech-enabled businesses. Listed on NASDAQ since March 2017, Hamilton Lane is classified within the GICS Asset Management & Custody Banks sub-industry and operates additional offices across Europe, North America, Asia Pacific, and the Middle East.
- Private market AUM growth drives fee-related earnings higher
- Alternative fundraising competition intensifies from Blackstone and KKR
- Capital allocation through dividends and share buybacks continues
| Net Income: 282.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -6.49 > 1.0 |
| NWC/Revenue: 40.95% < 20% (prev 32.02%; Δ 8.93% < -1%) |
| CFO/TA 0.11 > 3% & CFO 305.9m > Net Income 282.5m |
| Net Debt (115.4m) to EBITDA (602.5m): 0.19 < 3 |
| Current Ratio: 2.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (53.7m) vs 12m ago -1.40% < -2% |
| Gross Margin: 75.90% > 18% (prev 70.86%; Δ 5.04% > 0.5%) |
| Asset Turnover: 36.97% > 50% (prev 37.02%; Δ -0.04% > 0%) |
| Interest Coverage Ratio: 41.65 > 6 (EBIT TTM 592.7m / Interest Expense TTM 14.2m) |
| A: 0.13 (Total Current Assets 584.0m - Total Current Liabilities 227.0m) / Total Assets 2.74b |
| B: 0.26 (Retained Earnings 723.2m / Total Assets 2.74b) |
| C: 0.25 (EBIT TTM 592.7m / Avg Total Assets 2.36b) |
| D: 1.24 (Book Value of Equity 1.00b / Total Liabilities 807.6m) |
| Altman-Z'' = 4.71 = AA |
| DSRI: 1.03 (Receivables 217.9m/178.2m, Revenue 871.9m/733.1m) |
| GMI: 0.93 (GM 70.86% / 75.90%) |
| AQI: 0.88 (AQ_t 0.75 / AQ_t-1 0.85) |
| SGI: 1.19 (Revenue 871.9m / 733.1m) |
| TATA: -0.01 (NI 282.5m - CFO 305.9m) / TA 2.74b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of November 06, 2026, the stock is trading at USD 90.13 with a total of 760,566 shares traded. Over the past week, the price has changed by +5.22%, over one month by +3.21%, over three months by -9.98% and over the past year by -25.56%.
Current recommended Stop Loss: 80.80 (which is 10.4% or 2.4 ATR below the current price).
Hamilton Lane has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy HLNE.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 123.1 | 36.6% |
P/E Trailing = 14.0935
P/E Forward = 12.5313
P/S = 7.3016
P/B = 5.2137
P/EG = 1.39
Revenue TTM = 871.9m USD
EBIT TTM = 592.7m USD
EBITDA TTM = 602.5m USD
Long Term Debt = 278.4m USD (from longTermDebt, last fiscal year)
Short Term Debt = unknown (none)
Debt = 451.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 90.6m
Net Debt = 115.4m USD (calculated: Debt 451.6m - CCE 336.2m)
Enterprise Value = 6.48b USD (6.37b + Debt 451.6m - CCE 336.2m)
Interest Coverage Ratio = 41.65 (Ebit TTM 592.7m / Interest Expense TTM 14.2m)
EV/FCF = 21.94x (Enterprise Value 6.48b / FCF TTM 295.4m)
FCF Yield = 4.56% (FCF TTM 295.4m / Enterprise Value 6.48b)
FCF Margin = 33.88% (FCF TTM 295.4m / Revenue TTM 871.9m)
Net Margin = 32.40% (Net Income TTM 282.5m / Revenue TTM 871.9m)
Gross Margin = 75.90% ((Revenue TTM 871.9m - Cost of Revenue TTM 210.1m) / Revenue TTM)
Gross Margin QoQ = none% (prev 69.74%)
Tobins Q-Ratio = 2.37 (Enterprise Value 6.48b / Total Assets 2.74b)
Interest Expense / Debt = 3.15% (Interest Expense 14.2m / Debt 451.6m)
Taxrate = 16.87% (97.6m / 578.5m)
NOPAT = 492.7m (EBIT 592.7m * (1 - 16.87%))
Current Ratio = 2.57 (Total Current Assets 584.0m / Total Current Liabilities 227.0m)
Debt / Equity = 0.45 (Debt 451.6m / totalStockholderEquity, last quarter 1.00b)
Debt / EBITDA = 0.19 (Net Debt 115.4m / EBITDA 602.5m)
Debt / FCF = 0.39 (Net Debt 115.4m / FCF TTM 295.4m)
Total Stockholder Equity = 933.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.98% (Net Income 282.5m / Total Assets 2.74b)
RoE = 30.26% (Net Income TTM 282.5m / Total Stockholder Equity 933.6m)
RoCE = 48.90% (EBIT 592.7m / Capital Employed (Equity 933.6m + L.T.Debt 278.4m))
RoIC = 19.98% (NOPAT 492.7m / Invested Capital 2.47b)
WACC = 9.60% (E(6.37b)/V(6.82b) * Re(10.10%) + D(451.6m)/V(6.82b) * Rd(3.15%) * (1-Tc(0.17)))
Discount Rate = 10.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 17.04 | Cagr: -0.26%
[DCF] Terminal Value 68.81% ; FCFF base≈314.2m ; Y1≈279.0m ; Y5≈231.3m
[DCF] Fair Price = 68.05 (EV 3.07b - Net Debt 115.4m = Equity 2.95b / Shares 43.3m; r=9.60% [WACC]; 5y FCF grow -13.69% → 2.50% )
EPS Correlation: 95.87 | EPS CAGR: 23.30% | SUE: 1.51 | # QB: 2
Revenue Correlation: 92.72 | Revenue CAGR: 12.41% | SUE: -0.59 | # QB: 0
EPS current Quarter (2026-12-31): EPS=1.72 | Chg30d=+4.79% | Revisions=+38% | Analysts=7
EPS current Year (2027-03-31): EPS=7.27 | Chg30d=-2.65% | Revisions=-12% | GrowthEPS=+23.2% | GrowthRev=+29.5%
EPS next Year (2028-03-31): EPS=7.37 | Chg30d=-0.04% | Revisions=+0% | GrowthEPS=+1.4% | GrowthRev=+7.8%
[Analyst] Revisions Ratio: +12% (up=8, down=6)